Text Size:AAA

CD153 / CD30L / TNFSF8 항체, 토끼 다클론 항체, Antigen Affinity Purified

데이터시트리뷰프로토콜
발현 숙주: Human Cells  
  • Slide 1
10040-HNCH-50
10040-HNCH-200
50 µg 
200 µg 
Add to Cart
제품 설명: Active  
발현 숙주: Human Cells  
  • Slide 1
10040-H01H-50
10040-H01H-5
10040-H01H-100
50 µg 
5 µg 
100 µg 
Add to Cart
발현 숙주: Human Cells  
  • Slide 1
80148-RNCH-50
80148-RNCH-100
50 µg 
100 µg 
Add to Cart
발현 숙주: Human Cells  
  • Slide 1
80148-R01H-50
80148-R01H-100
50 µg 
100 µg 
Add to Cart
발현 숙주: Human Cells  
  • Slide 1
90091-C01H-50
90091-C01H-100
50 µg 
100 µg 
Add to Cart
발현 숙주: Human Cells  
  • Slide 1
90091-C07H-50
90091-C07H-100
50 µg 
100 µg 
Add to Cart

CD153/CD30L/TNFSF8  AntibodyRelated Products

Related Products

Featured Reagent Products

CD153/CD30L/TNFSF8  antibody 연구배경

CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.

필리핀원숭이 CD153/CD30L/TNFSF8  antibody 참고자료
  • Hargreaves PG, et al. (2002) Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol. 32(1): 163-73.
  • Blazar BR, et al. (2004) CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol. 173(5): 2933-41.
  • Oflazoglu E, et al. (2009) Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 647: 174-85.
  • 주의 : 모든 제품은 "연구 목적만을 위한 것이며 진단이나 치료에 사용하도록 의도되지 않았습니다".